Background: The rapid spread of SARS-CoV-2 has caused havoc and panic among individuals, which has
further worsened due to the unavailability of a proven drug(s) regime.
Objective: The current work involves drug repurposing from the pool of USFDA approved drugs involving in silico virtual
screening technique against Covid-19.
Methods: Methodology involves virtual screening of 8548 FDA approved drugs against target protein endoribonuclease
NendoU (Nsp15) (PDB ID: 6VWW).
Results: Virtual screening-based analysis enabled us to identify four drugs, Eprosartan, Inarigivir soproxil, Foretinib, and
DB01813 that could plausibly target Nsp15 against Covid-19 disease.
Conclusion: The work offers the scope to corroborate the findings via in vitro and in vivo techniques to identify the
potential of selected leads against Covid-19. The outcome may also help in tracing their molecular mechanism(s) in addition
to their development at the clinical level in the future.